Authors' Reply to the Letter on “Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First‐Line Helicobacter pylori Eradication Treatment More Effective? A Three‐Arm, Multicenter Randomized Clinical Trial”
Helicobacter · 2025
DOI: 10.1111/hel.70049 ↗Kurz gefasst
Leserbrief in der Zeitschrift Helicobacter, 2025. Verfasst von Zhengchen Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Clarithromycin, Bismuth, Anti-Bacterial Agents. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
We appreciate the valuable comments and thoughtful critique offered by the reader regarding our study on tailored bismuth quadruple therapy based on fecal molecular susceptibility testing in first‐line Helicobacter pylori eradication. In our response, we have sought to clarify the methodological rationale underlying our statistical analysis and terminology usage, particularly regarding superiority and non‐inferiority testing. We have also addressed concerns regarding assessing prior macrolide exposure, outlining the practical considerations that informed our study design. We trust that our clarifications will help to elucidate the study's context and findings further, and we welcome continued academic dialogue on this important topic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Nanxun People's Hospital, Huzhou, China.
- Longquan People's Hospital, Lishui, China.
ORCID-Profile: Guochun Lou, Jun Ye
Zitieren
APA
Yu, Z., Shen, W., Lou, G., Li, Y., Xie, Z., & Ye, J. (2025). Authors' Reply to the Letter on “Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First‐Line Helicobacter pylori Eradication Treatment More Effective? A Three‐Arm, Multicenter Randomized Clinical Trial”. Helicobacter. https://doi.org/10.1111/hel.70049
Vancouver
Yu Z, Shen W, Lou G, Li Y, Xie Z, Ye J. Authors' Reply to the Letter on “Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First‐Line Helicobacter pylori Eradication Treatment More Effective? A Three‐Arm, Multicenter Randomized Clinical Trial”. Helicobacter. 2025. doi:10.1111/hel.70049
BibTeX
@article{Yu2025,
author = {Yu, Zhengchen and Shen, Wenjuan and Lou, Guochun and Li, Yan and Xie, Ziming and Ye, Jun},
title = {Authors' Reply to the Letter on “Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First‐Line Helicobacter pylori Eradication Treatment More Effective? A Three‐Arm, Multicenter Randomized Clinical Trial”},
journal = {Helicobacter},
year = {2025},
doi = {10.1111/hel.70049}
}
EUVIMED